Zhao Jing, Mou Yongshan, Bernstock Joshua D, Klimanis Dace, Wang Sixian, Spatz Maria, Maric Dragan, Johnson Kory, Klinman Dennis M, Li Xiaohong, Li Xinhui, Hallenbeck John M
Department of Neurology, Jinan Central Hospital affiliated with Shandong University, 105 Jiefang Road, Jinan, Shandong, 250013, P. R. China; Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America.
Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2015 Oct 16;10(10):e0140772. doi: 10.1371/journal.pone.0140772. eCollection 2015.
The immune system plays a fundamental role in both the development and pathobiology of stroke. Inflammasomes are multiprotein complexes that have come to be recognized as critical players in the inflammation that ultimately contributes to stroke severity. Inflammasomes recognize microbial and host-derived danger signals and activate caspase-1, which in turn controls the production of the pro-inflammatory cytokine IL-1β. We have shown that A151, a synthetic oligodeoxynucleotide containing multiple telemeric TTAGGG motifs, reduces IL-1β production by activated bone marrow derived macrophages that have been subjected to oxygen-glucose deprivation and LPS stimulation. Further, we demonstrate that A151 reduces the maturation of caspase-1 and IL-1β, the levels of both the iNOS and NLRP3 proteins, and the depolarization of mitochondrial membrane potential within such cells. In addition, we have demonstrated that A151 reduces ischemic brain damage and NLRP3 mRNA levels in SHR-SP rats that have undergone permanent middle cerebral artery occlusion. These findings clearly suggest that the modulation of inflammasome activity via A151 may contribute to a reduction in pro-inflammatory cytokine production by macrophages subjected to conditions that model brain ischemia and modulate ischemic brain damage in an animal model of stroke. Therefore, modulation of ischemic pathobiology by A151 may have a role in the development of novel stroke prevention and therapeutic strategies.
免疫系统在中风的发生发展及病理生物学过程中发挥着重要作用。炎性小体是一种多蛋白复合物,现已被公认为是导致中风严重程度的炎症过程中的关键参与者。炎性小体识别微生物和宿主来源的危险信号并激活半胱天冬酶-1,进而控制促炎细胞因子白细胞介素-1β的产生。我们已经表明,A151是一种含有多个端粒TTAGGG基序的合成寡脱氧核苷酸,可减少经氧糖剥夺和脂多糖刺激的活化骨髓来源巨噬细胞产生白细胞介素-1β。此外,我们证明A151可降低此类细胞内半胱天冬酶-1和白细胞介素-1β的成熟度、诱导型一氧化氮合酶和NLRP3蛋白的水平以及线粒体膜电位的去极化。另外,我们已经证明A151可减少经历永久性大脑中动脉闭塞的SHR-SP大鼠的缺血性脑损伤和NLRP3 mRNA水平。这些发现清楚地表明,通过A151调节炎性小体活性可能有助于减少在模拟脑缺血条件下的巨噬细胞产生促炎细胞因子,并在中风动物模型中调节缺血性脑损伤。因此,A151对缺血病理生物学的调节可能在新型中风预防和治疗策略的开发中发挥作用。